Dr. Reddy's Laboratories Limited
NSE: DRREDDY | Information Technology
Market Fundamentals
Stock Intelligence & News
Zydus, Sun Pharma, Dr Reddy's In Focus: US Cancer Drug Shortage Puts India's Pharma Stocks In Focus
According to media reports, the regulator has communicated through the Indian Drug Manufacturers' Association (IDMA) to identify companies that can immediately supply ifosfamide injection, a generic chemotherapy drug used in the treatment of several cancers, including testicular, bladder and lung cancer.
Read Full Analysis →Dr Reddy's Labs Q1 Results: Date, Dividend, Share Price History, And More
Dr Reddy's Laboratories Ltd. saw an 86% YoY (year-on-year) plunge in Q4 net profit.
Read Full Analysis →Dr Reddy's Launches Oral Semaglutide Biosimilar Obeda In India
Dr Reddy's Laboratories
Read Full Analysis →AI-Powered Alerts for Your Portfolio
Alerfo's AI classifies every news event by type, severity, and market impact — then instantly notifies you via Email & WhatsApp only for the stocks you track.
Margin revival, Semaglutide launch to drive Dr Reddy’s growth momentum in FY27
Dr Reddy's Laboratories anticipates a gradual recovery this fiscal year. The company faced a profit drop last year due to US business pressures. However, operations in India, Europe, and emerging markets show healthy growth. New launches like Semaglutide and Abatacept are expected to drive future expansion. Margins are set to improve with better product mix and cost controls.
Read Full Analysis →Dr Reddy's Laboratories shares volatile after a 86% YoY decline in Q4 profit. Should you buy?
Dr Reddy shares swung between gains and losses in morning deals on the BSE on Wednesday, 13 May. It rose nearly 3% and then plunged 4% during the session.
Read Full Analysis →Dr Reddy's shares in focus after Q4 net profit tumbles 86% YoY; Morgan Stanley, Goldman Sachs weigh in
Dr. Reddy's Laboratories shares: The pharma major posted a sharp 86% YoY drop in Q4FY26 consolidated net profit to Rs 221 crore, compared with Rs 1,587 crore a year ago. Following the weak earnings performance, several brokerages cut their target prices on the stock.
Read Full Analysis →Dr Reddy's Q4 Disappoints Brokerages On Weak Quarter, Semaglutide Ramp-Up Delays — Check Targets
Brokerages broadly maintain a bearish view. Morgan Stanley cut its target price to Rs 1,215 from Rs 1,259. Citi maintained its Sell call, and Jefferies echoed the sentiment, with an Underperform rating.
Read Full Analysis →Dr. Reddy's Target Price Cut by Motilal Oswal After Weak Q4 — Buy, Sell or Hold?
Dr Reddy's Labs delivered lower-than-expected Q4 performance with a 4%/32%/43% miss on sales/Ebitda/PAT.
Read Full Analysis →Dr Reddy's Q4 Results: Profit Plunges 86% As One-Time Costs Weigh; Dividend Declared, Check Record Date
The company's net profit was At Rs 221 crore from Rs 1,593 crore in the year-ago period.
Read Full Analysis →Get instant alerts when DRREDDY breaks news
Join investors who track Dr. Reddy's Laboratories Limited on Alerfo — free plan available.
Set Free Alert →Frequently Asked Questions
What is the current trend for DRREDDY?
DRREDDY is currently showing a volatility profile consistent with its sector peers, with sentiment being actively monitored by Alerfo news scanners.
How can I set alerts for Dr. Reddy's Laboratories Limited?
You can set real-time price and news alerts by registering on the Alerfo platform and adding DRREDDY to your custom watchlist.